Colonocyte metabolism shapes the gut microbiota

Science

Volumn 362, Issue 6418, 2018, Pages

  Litvak, Yael ^a   Byndloss, Mariana X ^a   Bäumler, Andreas J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN;

ANAEROBIC BACTERIUM; ARTICLE; CELL METABOLISM; CITROBACTER RODENTIUM; COLON CELL; COLON EPITHELIUM; COLON FLORA; DIETARY FIBER; DYSBIOSIS; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FERMENTATION; HUMAN; HYPOXIA; INTESTINE FLORA; MICROBIAL COMMUNITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SALMONELLA ENTERICA; ULCERATIVE COLITIS; CELL POLARITY; COLON; CYTOLOGY; HOST PATHOGEN INTERACTION; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY;

CELL POLARITY; COLITIS, ULCERATIVE; COLON; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINAL MUCOSA; OXYGEN CONSUMPTION;

EID: 85057537429     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aat9076     Document Type: Article

References (85)

1. P. D. Cani, Gut microbiota—at the intersection of everything? Nat. Rev. Gastroenterol. Hepatol. 14, 321–322 (2017). doi: 10.1038/nrgastro.2017.54; pmid: 28442782
2. P. B. Eckburg et al., Diversity of the human intestinal microbial flora. Science 308, 1635–1638 (2005). doi: 10.1126/ science.1110591; pmid: 15831718
3. J. Tap et al., Towards the human intestinal microbiota phylogenetic core. Environ. Microbiol. 11, 2574–2584 (2009). doi: 10.1111/j.1462-2920.2009.01982.x; pmid: 19601958
4. P. J. Turnbaugh et al., The effect of diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 1, 6ra14 (2009). doi: 10.1126/ scitranslmed.3000322; pmid: 20368178
5. K. R. Foster, J. Schluter, K. Z. Coyte, S. Rakoff-Nahoum, The evolution of the host microbiome as an ecosystem on a leash. Nature 548, 43–51 (2017). doi: 10.1038/nature23292; pmid: 28770836
6. G. den Besten et al., The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340 (2013). doi: 10.1194/ jlr.R036012; pmid: 23821742
7. O. C. Velázquez, H. M. Lederer, J. L. Rombeau, Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications. Adv. Exp. Med. Biol. 427, 123–134 (1997). pmid: 9361838
8. K. Atarashi et al., Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337–341 (2011). doi: 10.1126/science.1198469; pmid: 21205640
9. N. Arpaia et al., Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455 (2013). doi: 10.1038/nature12726; pmid: 24226773
10. Y. Furusawa et al., Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446–450 (2013). doi: 10.1038/nature12721; pmid: 24226770
11. reg cell homeostasis. Science 341, 569–573 (2013). doi: 10.1126/science.1241165; pmid: 23828891
12. M. X. Byndloss et al., Microbiota-activated PPAR-g signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 357, 570–575 (2017). doi: 10.1126/science.aam9949; pmid: 28798125
13. N. T. Porter, E. C. Martens, The Critical Roles of Polysaccharides in Gut Microbial Ecology and Physiology. Annu. Rev. Microbiol. 71, 349–369 (2017). doi: 10.1146/ annurev-micro-102215-095316; pmid: 28657886
14. A. El Kaoutari, F. Armougom, J. I. Gordon, D. Raoult, B. Henrissat, The abundance and variety of carbohydrate-active enzymes in the human gut microbiota. Nat. Rev. Microbiol. 11, 497–504 (2013). doi: 10.1038/nrmicro3050; pmid: 23748339
15. D. N. Bronner et al., Genetic Ablation of Butyrate Utilization Attenuates Gastrointestinal Salmonella Disease. Cell Host Microbe 23, 266–273.e4 (2018). doi: 10.1016/ j.chom.2018.01.004; pmid: 29447698
16. L. Spiga et al., An Oxidative Central Metabolism Enables Salmonella to Utilize Microbiota-Derived Succinate. Cell Host Microbe 22, 291–301.e6 (2017). doi: 10.1016/ j.chom.2017.07.018; pmid: 28844888
17. M. X. Byndloss, A. J. Bäumler, The germ-organ theory of noncommunicable diseases. Nat. Rev. Microbiol. 16, 103–110 (2018). doi: 10.1038/nrmicro.2017.158; pmid: 29307890
18. N. Barker, M. van de Wetering, H. Clevers, The intestinal stem cell. Genes Dev. 22, 1856–1864 (2008). doi: 10.1101/ gad.1674008; pmid: 18628392
19. Y. Y. Fan et al., A bioassay to measure energy metabolism in mouse colonic crypts, organoids, and sorted stem cells. Am. J. Physiol. Gastrointest. Liver Physiol. 309, G1–G9 (2015). doi: 10.1152/ajpgi.00052.2015; pmid: 25977509
20. O. Warburg, F. Wind, E. Negelein, The Metabolism of Tumors in the Body. J. Gen. Physiol. 8, 519–530 (1927). doi: 10.1085/ jgp.8.6.519; pmid: 19872213
21. Z. Tylichová et al., Activation of autophagy and PPARg protect colon cancer cells against apoptosis induced by interactive effects of butyrate and DHA in a cell type-dependent manner: The role of cell differentiation. J. Nutr. Biochem. 39, 145–155 (2017). doi: 10.1016/j.jnutbio.2016.09.006; pmid: 27840291
22. M. Lefebvre et al., Peroxisome proliferator-activated receptor g is induced during differentiation of colon epithelium cells. J. Endocrinol. 162, 331–340 (1999). doi: 10.1677/ joe.0.1620331; pmid: 10467224
23. K. Duszka, M. Oresic, C. Le May, J. König, W. Wahli, PPARg Modulates Long Chain Fatty Acid Processing in the Intestinal Epithelium. Int. J. Mol. Sci. 18, 2559 (2017). doi: 10.3390/ ijms18122559; pmid: 29182565
24. D. R. Donohoe et al., The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 13, 517–526 (2011). doi: 10.1016/ j.cmet.2011.02.018; pmid: 21531334
25. W. E. Roediger, Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21, 793–798 (1980). doi: 10.1136/gut.21.9.793; pmid: 7429343
26. G. T. Furuta et al., Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J. Exp. Med. 193, 1027–1034 (2001). doi: 10.1084/jem.193.9.1027; pmid: 11342587
27. Y. Litvak, M. X. Byndloss, R. M. Tsolis, A. J. Bäumler, Dysbiotic Proteobacteria expansion: A microbial signature of epithelial dysfunction. Curr. Opin. Microbiol. 39, 1–6 (2017). doi: 10.1016/ j.mib.2017.07.003; pmid: 28783509
28. N. R. Shin, T. W. Whon, J. W. Bae, Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 33, 496–503 (2015). doi: 10.1016/j.tibtech.2015.06.011; pmid: 26210164
29. G. Rizzatti, L. R. Lopetuso, G. Gibiino, C. Binda, A. Gasbarrini, Proteobacteria: A Common Factor in Human Diseases. BioMed Res. Int. 2017, 9351507 (2017). doi: 10.1155/2017/9351507; pmid: 29230419
30. E. J. Vollaard, H. A. Clasener, A. J. Janssen, Co-trimoxazole impairs colonization resistance in healthy volunteers. J. Antimicrob. Chemother. 30, 685–691 (1992). doi: 10.1093/ jac/30.5.685; pmid: 1493984
31. -/- mice. Nature 487, 104–108 (2012). doi: 10.1038/nature11225; pmid: 22722865
32. M. Martinez-Medina et al., Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut 63, 116–124 (2014). doi: 10.1136/gutjnl-2012-304119; pmid: 23598352
33. X. C. Morgan et al., Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 13, R79 (2012). doi: 10.1186/gb-2012-13-9-r79; pmid: 23013615
34. J. C. Arthur et al., Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120–123 (2012). doi: 10.1126/science.1224820; pmid: 22903521
35. I. M. Carroll, T. Ringel-Kulka, J. P. Siddle, Y. Ringel, Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 24, 521–530 (2012). doi: 10.1111/ j.1365-2982.2012.01891.x; pmid: 22339879
36. L. Krogius-Kurikka et al., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 9, 95 (2009). doi: 10.1186/1471-230X-9-95; pmid: 20015409
37. E. Normann, A. Fahlén, L. Engstrand, H. E. Lilja, Intestinal microbial profiles in extremely preterm infants with and without necrotizing enterocolitis. Acta Paediatr. 102, 129–136 (2013). doi: 10.1111/apa.12059; pmid: 23082780
38. L. Rigottier-Gois, Dysbiosis in inflammatory bowel diseases: The oxygen hypothesis. ISME J. 7, 1256–1261 (2013). doi: 10.1038/ismej.2013.80; pmid: 23677008
39. F. Rivera-Chávez, C. A. Lopez, A. J. Bäumler, Oxygen as a driver of gut dysbiosis. Free Radic. Biol. Med. 105, 93–101 (2017). doi: 10.1016/j.freeradbiomed.2016.09.022; pmid: 27677568
40. C. J. Kelly et al., Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe 17, 662–671 (2015). doi: 10.1016/j.chom.2015.03.005; pmid: 25865369
41. S. Alex et al., Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor g. Mol. Cell. Biol. 33, 1303–1316 (2013). doi: 10.1128/MCB.00858-12; pmid: 23339868
42. A. M. Spees et al., Streptomycin-induced inflammation enhances Escherichia coli gut colonization through nitrate respiration. mBio 4, e00430-13 (2013). doi: 10.1128/ mBio.00430-13; pmid: 23820397
43. C. C. Gillis et al., Dysbiosis-Associated Change in Host Metabolism Generates Lactate to Support Salmonella Growth. Cell Host Microbe 23, 54–64.e6 (2018). doi: 10.1016/ j.chom.2017.11.006; pmid: 29276172
44. A. T. Reese et al., Antibiotic-induced changes in the microbiota disrupt redox dynamics in the gut. eLife 7, e35987 (2018). doi: 10.7554/eLife.35987; pmid: 29916366
45. X. Geeraerts, E. Bolli, S. M. Fendt, J. A. Van Ginderachter, Macrophage Metabolism As Therapeutic Target for Cancer, Atherosclerosis, and Obesity. Front. Immunol. 8, 289 (2017). doi: 10.3389/fimmu.2017.00289; pmid: 28360914
46. I. F. Charo, Macrophage polarization and insulin resistance: PPARg in control. Cell Metab. 6, 96–98 (2007). doi: 10.1016/ j.cmet.2007.07.006; pmid: 17681144
47. S. E. Winter et al., Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339, 708–711 (2013). doi: 10.1126/ science.1232467; pmid: 23393266
48. O. Papapietro et al., R-spondin 2 signalling mediates susceptibility to fatal infectious diarrhoea. Nat. Commun. 4, 1898 (2013). doi: 10.1038/ncomms2816; pmid: 23695692
49. V. Strugala, P. W. Dettmar, J. P. Pearson, Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. Int. J. Clin. Pract. 62, 762–769 (2008). doi: 10.1111/j.1742-1241.2007.01665.x; pmid: 18194279
50. D. A. McCormick, L. W. Horton, A. S. Mee, Mucin depletion in inflammatory bowel disease. J. Clin. Pathol. 43, 143–146 (1990). doi: 10.1136/jcp.43.2.143; pmid: 2318990
51. L. Dubuquoy et al., Impaired expression of peroxisome proliferator-activated receptor g in ulcerative colitis. Gastroenterology 124, 1265–1276 (2003). doi: 10.1016/ S0016-5085(03)00271-3; pmid: 12730867
52. W. E. Roediger, The colonic epithelium in ulcerative colitis: An energy-deficiency disease? Lancet ii, 712–715 (1980). doi: 10.1016/S0140-6736(80)91934-0; pmid: 6106826
53. A. Ponferrada et al., The role of PPARg on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 132, 1791–1803 (2007). doi: 10.1053/j.gastro.2007.02.032; pmid: 17484875
54. N. Ogasawara et al., PPARg agonists upregulate the barrier function of tight junctions via a PKC pathway in human nasal epithelial cells. Pharmacol. Res. 61, 489–498 (2010). doi: 10.1016/j.phrs.2010.03.002; pmid: 20227502
55. C. A. Lopez et al., Virulence factors enhance Citrobacter rodentium expansion through aerobic respiration. Science 353, 1249–1253 (2016). doi: 10.1126/science.aag3042; pmid: 27634526
56. S. P. Dudhgaonkar, S. K. Tandan, D. Kumar, V. Raviprakash, M. Kataria, Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Inflammopharmacology 15, 188–195 (2007). doi: 10.1007/s10787-007-1603-3; pmid: 17943250
57. E. R. Hughes et al., Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis. Cell Host Microbe 21, 208–219 (2017). doi: 10.1016/ j.chom.2017.01.005; pmid: 28182951
58. M. A. Henson, P. Phalak, Microbiota dysbiosis in inflammatory bowel diseases: In silico investigation of the oxygen hypothesis. BMC Syst. Biol. 11, 145 (2017). doi: 10.1186/s12918-017-0522-1; pmid: 29282051
59. K. J. Khan et al., Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. Am. J. Gastroenterol. 106, 661–673 (2011). doi: 10.1038/ ajg.2011.72; pmid: 21407187
60. E. E. Olsan et al., Colonization resistance: The deconvolution of a complex trait. J. Biol. Chem. 292, 8577–8581 (2017). doi: 10.1074/jbc.R116.752295; pmid: 28389556
61. W. Zhu et al., Precision editing of the gut microbiota ameliorates colitis. Nature 553, 208–211 (2018). doi: 10.1038/ nature25172; pmid: 29323293
62. V. M. Rekdal, E. P. Balskus, Gut Microbiota: Rational Manipulation of Gut Bacterial Metalloenzymes Provides Insights into Dysbiosis and Inflammation. Biochemistry 57, 2291–2293 (2018). doi: 10.1021/acs.biochem.8b00340; pmid: 29633827
63. C. Rousseaux et al., The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARg. Carcinogenesis 34, 2580–2586 (2013). doi: 10.1093/carcin/bgt245; pmid: 23843037
64. R. N. Brogden, E. M. Sorkin, Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 38, 500–523 (1989). doi: 10.2165/00003495-198938040-00003; pmid: 2684592
65. S. M. Greenfield, N. A. Punchard, J. P. Teare, R. P. Thompson, The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment. Pharmacol. Ther. 7, 369–383 (1993). doi: 10.1111/j.1365-2036.1993.tb00110.x; pmid: 8105984
66. S. Y. Zhou et al., Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab. Dispos. 27, 479–485 (1999). pmid: 10101143
67. C. Rousseaux et al., Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-g. J. Exp. Med. 201, 1205–1215 (2005). doi: 10.1084/jem.20041948; pmid: 15824083
68. J. Xu et al., 5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. Front. Microbiol. 9, 1274 (2018). doi: 10.3389/fmicb.2018.01274; pmid: 29951050
69. E. Muraille, O. Leo, M. Moser, TH1/TH2 paradigm extended: Macrophage polarization as an unappreciated pathogen-driven escape mechanism? Front. Immunol. 5, 603 (2014). doi: 10.3389/fimmu.2014.00603; pmid: 25505468
70. M. N. Xavier et al., PPARg-mediated increase in glucose availability sustains chronic Brucella abortus infection in alternatively activated macrophages. Cell Host Microbe 14, 159–170 (2013). doi: 10.1016/j.chom.2013.07.009; pmid: 23954155
71. B. Stecher et al., Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLOS Biol. 5, e244 (2007). doi: 10.1371/journal. pbio.0050244; pmid: 17760501
72. I. Sekirov et al., Salmonella SPI-1-mediated neutrophil recruitment during enteric colitis is associated with reduction and alteration in intestinal microbiota. Gut Microbes 1, 30–41 (2010). doi: 10.4161/gmic.1.1.10950; pmid: 21327114
73. N. Gill et al., Neutrophil elastase alters the murine gut microbiota resulting in enhanced Salmonella colonization. PLOS ONE 7, e49646 (2012). doi: 10.1371/journal. pone.0049646; pmid: 23155475
74. F. Rivera-Chávez et al., Depletion of Butyrate-Producing Clostridia from the Gut Microbiota Drives an Aerobic Luminal Expansion of Salmonella. Cell Host Microbe 19, 443–454 (2016). doi: 10.1016/j.chom.2016.03.004; pmid: 27078066
75. C. A. Lopez et al., Phage-mediated acquisition of a type III secreted effector protein boosts growth of salmonella by nitrate respiration. mBio 3, e00143-12 (2012). doi: 10.1128/ mBio.00143-12; pmid: 22691391
76. C. A. Lopez, F. Rivera-Chávez, M. X. Byndloss, A. J. Bäumler, The Periplasmic Nitrate Reductase NapABC Supports Luminal Growth of Salmonella enterica Serovar Typhimurium during Colitis. Infect. Immun. 83, 3470–3478 (2015). doi: 10.1128/ IAI.00351-15; pmid: 26099579
77. S. E. Winter et al., Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature 467, 426–429 (2010). doi: 10.1038/nature09415; pmid: 20864996
78. P. Thiennimitr et al., Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota. Proc. Natl. Acad. Sci. U.S.A. 108, 17480–17485 (2011). doi: 10.1073/pnas.1107857108; pmid: 21969563
79. F. Faber et al., Respiration of Microbiota-Derived 1,2-propanediol Drives Salmonella Expansion during Colitis. PLOS Pathog. 13, e1006129 (2017). doi: 10.1371/journal. ppat.1006129; pmid: 28056091
80. J. W. Collins et al., Citrobacter rodentium: Infection, inflammation and the microbiota. Nat. Rev. Microbiol. 12, 612–623 (2014). doi: 10.1038/nrmicro3315; pmid: 25088150
81. N. Kamada et al., Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. Science 336, 1325–1329 (2012). doi: 10.1126/science.1222195; pmid: 22582016
82. C. Lupp et al., Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2, 204 (2007). doi: 10.1016/j.chom.2007.08.002; pmid: 18030708
83. V. Kumar et al., miR-130a and miR-212 Disrupt the Intestinal Epithelial Barrier through Modulation of PPARg and Occludin Expression in Chronic Simian Immunodeficiency Virus-Infected Rhesus Macaques. J. Immunol. 200, 2677–2689 (2018). doi: 10.4049/jimmunol.1701148; pmid: 29514950
84. E. A. Mutlu et al., A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLOS Pathog. 10, e1003829 (2014). doi: 10.1371/journal.ppat.1003829; pmid: 24586144
85. A. Carreau, B. El Hafny-Rahbi, A. Matejuk, C. Grillon, C. Kieda, Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J. Cell. Mol. Med. 15, 1239–1253 (2011). doi: 10.1111/j.1582-4934.2011.01258.x; pmid: 21251211